SCHEMBL29205337

SCHEMBL29205337

Cc1ncn(-c2ncc([N+](=O)[O-])cc2O)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.41
HPGD P15428 3/20 0.41
CYP1A2 P05177 2/20 0.41
HIF1A Q16665 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP2D6 P10635 1/20 0.41
HTT P42858 4/20 0.39
MAPK1 P28482 2/20 0.39
MAPT P10636 4/20 0.36
POLB P06746 1/20 0.36
CHEK1 O14757 1/20 0.35
DAPK3 O43293 1/20 0.35
GRK5 P34947 1/20 0.35
LIMK1 P53667 1/20 0.35
GAA P10253 1/20 0.34
GPR35 Q9HC97 2/20 0.34
KDM4E B2RXH2 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
MEN1 O00255 1/20 0.34
TTR P02766 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29205268 0.81 KMT2A (0.41) ALDH1A1HTTMAPK1MAPTTDP1
SCHEMBL30899602 0.78 ALDH1A1 (0.46) ALDH1A1HPGDCYP1A2HIF1AHSD17B10
SCHEMBL29205263 0.78 ALDH1A1 (0.46) ALDH1A1HPGDCYP1A2HIF1AHSD17B10
SCHEMBL13412120 0.75 ALDH1A1 (0.44) ALDH1A1HPGDCYP1A2HIF1AHSD17B10
SCHEMBL31481312 0.75 ALDH1A1 (0.44) ALDH1A1HPGDCYP1A2HIF1AHSD17B10
SCHEMBL29205318 0.72 MAPT (0.51) ALDH1A1HPGDCYP1A2MAPTPOLB
SCHEMBL6803506 0.71 FGFR1 (0.60) ALDH1A1HPGDMAPTPOLBMEN1
SCHEMBL30310967 0.70 ALDH1A1 (0.52) ALDH1A1HPGDHIF1AHTTMAPK1
SCHEMBL6754345 0.69 MEN1 (0.41) ALDH1A1HPGDCYP1A2HIF1AHSD17B10
SCHEMBL27579425 0.68 ALDH1A1 (0.47) ALDH1A1HPGDCYP1A2HIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof GISMO THERAPEUTICS, INC. 2024-12-05 US disclosed
CN-117999075-A Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof 吉斯莫治疗股份有限公司 2024-05-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof PRNP, GBA1, GBA3 ALDH1A1 3486/4885HPGD 1285/4885CYP1A2 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.